文献速递生殖医学母胎医学

整倍体胚胎移植后产前游离DNA筛查染色体非整倍体与胚胎植入前非整倍体遗传学检测结果高度一致且阳性预测值低

Prenatal cell-free DNA screening for chromosomal aneuploidies after euploid embryo transfer shows high concordance with preimplantation genetic testing for aneuploidy results and low positive predictive values.
PubMed 文献 · Fertil Steril · 2024-07-27

单中心回顾性队列研究纳入2973例单胎妊娠产前cfDNA筛查结果,比较PGT-A组(n=1204,单整倍体胚胎移植后)与非PGT-A组(n=1769,单未检测胚胎移植后)。PGT-A组异常cfDNA筛查阳性预测值为7.7%,非PGT-A组为38%;性染色体结果与PGT-A 100%一致。

要点

  • PGT-A组异常产前cfDNA筛查阳性预测值为7.7%,非PGT-A组为38%。
  • 两组胎儿分数无差异(9.5%±4% vs 10.3%±4%)。
  • 性染色体产前cfDNA筛查与PGT-A结果100%一致,PGT-A对性染色体阳性预测值100%。

核心结论

  • 接受体外受精/PGT-A及单整倍体胚胎移植的患者可在早孕期可靠地进行产前cfDNA筛查。
  • PGT-A检测后单胎妊娠的胎儿分数与未检测胚胎妊娠无差异。
  • 整倍体胚胎移植后异常产前cfDNA筛查的阳性预测值低至令人安心的7.7%。
  • PGT-A可靠地筛选非整倍体,与胎儿性别100%一致。

研究设计与样本

  • 单中心回顾性队列研究,于生育门诊开展,纳入2016年至2023年间单胎妊娠的2973例产前cfDNA筛查结果。
  • PGT-A组(n=1204)为单整倍体胚胎移植后妊娠,非PGT-A组(n=1769)为单未检测胚胎移植后妊娠。
  • 产前cfDNA筛查覆盖常见三体(T13、T18、T21、X、Y)及微缺失(1p36、4p16.3、5p15.2、15q11.2、22q11.2)。
  • 主要结局为产前cfDNA筛查准确性,通过阳性/阴性筛查结果及后续产前或产后诊断检测将阳性结果分类为真阳性或假阳性。

主要发现

  • 产前cfDNA筛查平均在孕11.3±1.8周进行,99.9%的患者获得结果(取消率0.1%)。
  • PGT-A检测与未检测妊娠的胎儿分数无差异(9.5%±4% vs 10.3%±4%)。
  • PGT-A组收到13例产前cfDNA筛查阳性结果(2例T21、2例X0、4例XXX、1例XYY、1例性别不确定、2例22q11 del/dup、1例15q11.2del),仅1例(22q11 dup)经羊膜腔穿刺和胎儿尸检确认,异常产前cfDNA筛查的阳性预测值为7.7%,其余结果与PGT-A一致。
  • 性染色体产前cfDNA筛查与PGT-A结果100%一致,PGT-A对性染色体的阳性预测值为100%,对非整倍体的阴性预测值为100%。
  • 非PGT-A组27例妊娠(1.5%)收到产前cfDNA筛查阳性结果,21例选择性进行随访检测,8例确认产前cfDNA筛查结果,非PGT-A组阳性预测值为38%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the positive predictive value (PPV) of prenatal cell-free DNA (cfDNA) screening for chromosomal aneuploidies in pregnancies achieved either after single euploid transfer in in vitro fertilization or Preimplantation Genetic Testing for Aneuploidy (PGT-A) cycles or transfer of single untested embryo, and to assess the concordance of prenatal-cfDNA-screening and PGT-A results. DESIGN: Single center retrospective cohort study. SETTING: Fertility clinic. PATIENT(S): A total of 2,973 prenatal-cfDNA-screening results for the most common trisomies (T13, T18, T21, X, and Y) and microdeletions (1p36, 4p16.3, 5p15.2, 15q11.2, and 22q11.2) from singleton pregnancies allocated into two groups: PGT-A group (n = 1,204) pregnant after single euploid transfer and non-PGT-A group (n = 1769) pregnant after transfer of single untested embryo, between 2016 and 2023. INTERVENTION(S): Not applicable. MAIN OUTCOME MEASURE(S): The primary outcome measure was the accuracy of prenatal-cfDNA screening. Positive and negative prenatal-cfDNA-screening results and subsequent prenatal or postnatal diagnostic testing were used to classify each positive prenatal-cfDNA-screening result as a true or a false positive. Secondary endpoints were to evaluate the concordance of PGT-A and prenatal-cfDNA-screening results and to assess the differences in the fetal fraction of cfDNA used for prenatal-cfDNA-screening reports between the study groups. RESULT(S): Prenatal-cfDNA screening was performed at a mean 11.3 ± 1.8 weeks gestational age, and yielded results in 99.9% of the patients (0.1% cancellation rate). There was no difference in the fetal fraction between PGT-A tested and not tested pregnancies (9.5% ± 4% vs. 10.3% ± 4%). 13 positive prenatal-cfDNA-screening results (two T21, two X0, four XXX, one XYY, one indeterminate sex, two 22q11 del/dup, and one 15q11.2del) were received for PGT-A group. Only one (22q11 dup) was confirmed with amniocentesis and fetal autopsy, giving a PPV for an abnormal prenatal-cfDNA screening of 7.7%, the rest had results concordant with PGT-A. Sex chromosomes were 100% concordant between prenatal-cfDNA-screening and PGT-A results, giving a 100% PPV for PGT-A for sex chromosomes and 100% negative predictive value for aneuploidies. Positive prenatal-cfDNA-screening results were received for 27 pregnancies from untested embryos (1.5%), follow-up testing was electively performed for 21, and 8 had confirmed the prenatal-cfDNA-screening result, giving a PPV for the non-PGT-A group of 38%. CONCLUSION(S): This study demonstrates that patients undergoing in vitro fertilization/PGT-A and single euploid embryo transfer can reliably do prenatal-cfDNA screening during their first trimester. Fetal fraction in singleton pregnancies after PGT-A tested embryos is not different from pregnancies with untested embryos. Positive predictive value for an abnormal prenatal-cfDNA-screening result after euploid embryo transfer was reassuringly low (7.7%). PGT-A reliably selects against aneuploidy with 100% concordance with fetal sex.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Madjunkov M, Sharma P, Baratz A, et al. Prenatal cell-free DNA screening for chromosomal aneuploidies after euploid embryo transfer shows high concordance with preimplantation genetic testing for aneuploidy results and low positive predictive values. Fertil Steril. 2024. PMID: 39069216. doi:10.1016/j.fertnstert.2024.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。